Congo - Towards local production of medicines

The price of medicines is a barrier to accessing quality healthcare for the majority of Congolese people. The government hopes to increase private investment in pharmaceutical production.

Position

Reference

Space not available

Reserve this advertising space

Selected ad format

The file format is not recognized

Click here for
upload an ad

Click here to download
an announcement

Here drag and drop or
upload an ad

Send the ad up to 8 days after payment
A link will be sent to you by contact@via-agency.media

Reserved space
Announcement transmitted

If you want another location, you can move this ad

Reference

The countries that signed the Lomé Initiative, including the Congo, have decided to criminalize the trafficking of substandard and falsified medical products. The Congo-Brazzaville intends to legalize the monopoly on the practice of qualified pharmacists and medical biologists and to implement measures to promote the national pharmaceutical industry.

In the market for injectable solution bags for infusion medicines, with a fleet of state-of-the-art pharmaceutical machines employing highly sophisticated technologies, the Biocare laboratory was established in Congo in 2012-2013 with the aim of meeting the needs of hospitals in terms of quality and quantity.

In April 2023, the pharmaceutical company Biogaran announced the expansion of its operations in the Dolisie region to democratize access to quality generic medicines and extend its territorial coverage in the Republic of Congo, three years after its launch in Brazzaville and Pointe-Noire. Biogaran, a leading generic drug manufacturer in France, markets a wide range of nearly 100 medications in Congo, produced at a rate of 51% in France and 91% in Europe, enabling the treatment of some of the most common illnesses in the country at a lower cost.

Position

Reference

Space not available

Reserve this advertising space

Selected ad format

The file format is not recognized

Click here for
upload an ad

Click here to download
an announcement

Here drag and drop or
upload an ad

Send the ad up to 8 days after payment
A link will be sent to you by contact@via-agency.media

Reserved space
Announcement transmitted

If you want another location, you can move this ad

Reference

The use of generic drugs in Congo-Brazzaville is estimated at no more than 301,000,000,000,000,000,000, yet they represent a valuable alternative. Meeting international standards, generic drugs are as effective as the original medication but, being significantly less expensive, they allow patients access to healthcare at a lower cost. The WHO estimates that the use of generic drugs significantly reduces the cost of medicines for both governments and patients.

A significant and positive example of the impact of generic drugs concerns the evolution of prices for antiretroviral medications used to treat HIV. According to the WHO, the cost of therapy per patient per year has fallen from $10,000 to less than $100 following the introduction of generic drugs to the market, which has considerably increased access to treatment: in 2003, only 500,000 people benefited from this care, compared to 15.8 million in 2015. This is a considerable advancement, allowing patients access to treatment.

Regulatory harmonization and improvement of pharmacovigilance processes is an issue seized by the member countries of the Economic and Monetary Community of Central Africa (CEMAC) and the West African Economic and Monetary Union (UEMOA).